Loading data for ALDX — first visit, this takes a few seconds.

Alert

Aldeyra Therapeutics Inc. (ALDX)

NasdaqCM: ALDX · Real-Time Price · USD

1.58

+0.03 (1.94%)

At close: Aug 20, 2026, 4:07 PM

1.94% (1D)

No data available

Bid	1.15
Market Cap	92M
Revenue (ttm)	n/a
Net Income (ttm)	-23.05M
Beta	1.20
EPS (ttm)	-0.38
PE Ratio (ttm)	n/a
Forward PE	-5.55
P/B (ttm)	2.43
P/S (ttm)	n/a
Earnings Date	Nov 4, 2026

Ask	1.62
Volume	979,453
Avg. Volume (20D)	1,355,235
Open	1.59
Previous Close	1.55
Day's Range	1.54 - 1.60
52-Week Range	1.07 - 6.17
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About ALDX

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. T...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date May 2, 2014

Employees 6

Stock Exchange NasdaqCM

Ticker Symbol ALDX

Website https://www.aldeyra.com

Full Company Profile

Financial Performance

In 2025, Aldeyra Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -33.85M, a decrease of -39.4%.

Financial Statements

Earnings Surprise

Aldeyra Therapeutics has released their quarterly earnings on Aug 6, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.

EPS of -0.09 misses estimates by -0.01, with 43.75% YoY growth.

Next Earnings Release

Aldeyra Therapeutics Inc. is scheduled to release its earnings on Nov 4, 2026, during market hours.
Analysts project revenue of ... Upgrade

News

2 months ago · Simply Wall St.

CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock

Investors who take an interest in Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) should definitely note that the CEO...

2 months ago · MarketBeat

Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment

Aldeyra Therapeutics (NASDAQ:ALDX) Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, follow...

2 months ago · Simply Wall St.

3 Promising Penny Stocks With Market Caps Reaching $300M

The market remained flat over the last week, but it is up 26% over the past year, with earnings forecast to grow by 17% annually. Investing in penny stocks—once a buzzword but now more of a niche—can ...

3 months ago · Simply Wall St.

Upstart Holdings Leads These 3 Stocks Estimated To Be Trading Below Fair Value

Over the last 7 days, the United States market has risen by 1.1%, and over the past 12 months, it is up by an impressive 27%, with earnings expected to grow by 17% per annum in the coming years. In th...

3 months ago · Simply Wall St.

3 Stocks That May Be Undervalued According To Analysts In May 2026

Over the last 7 days, the United States market has risen by 1.1%, contributing to a remarkable 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environm...

Page 1 of 2

Aldeyra Therapeutics Inc. (ALDX)